Expertise in
4
conditions

Ignacio Bazo-Gil

Pamplona, NC, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
Pamplona, NC, ES 

Overview

Ignacio Bazo-Gil practices practicing medicine in Pamplona, Spain.

Mr. Bazo-Gil is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

He is actively involved in clinical research, co-authoring 85 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Pamplona, NC, Spain
Other Locations
Madrid, MD, Spain
Valencia, VC, Spain
Gasteiz / Vitoria, PV, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Paclitaxel, Carboplatin
Study Phase: Phase 2
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
Analysis of Soluble Mediators, Cytokines, and Circulating Angiogenic Factors (FACs) as Potential Predictors / Prognostic Factors in Antiangiogenic Therapy Following Failure of First-line Chemotherapy in Advanced Non-squamous Lung Carcinoma
Analysis of Soluble Mediators, Cytokines, and Circulating Angiogenic Factors (FACs) as Potential Predictors / Prognostic Factors in Antiangiogenic Therapy Following Failure of First-line Chemotherapy in Advanced Non-squamous Lung Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2023
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Enrollment Status: Completed
Publish Date: June 27, 2022
View 4 Less Clinical Trials

85 Total Publications

Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response prediction.
Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response prediction.
Journal: Computers in biology and medicine
Published: July 18, 2025

Frequently Asked Questions about Ignacio Bazo-Gil

Is Ignacio Bazo-Gil a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Ignacio Bazo-Gil is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ignacio Bazo-Gil participate in research or clinical trials?

Yes. Ignacio Bazo-Gil has published 85 articles and abstracts on conditions like Lung Cancer. You can view a list of Ignacio Bazo-Gil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bazo-Gil's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile